BOUCHERVILLE, QC, Nov. 6, 2024 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) , (TSXV: LSL.DB) ("LSL Pharma" or the "Corporation"), an integrated Canadian-based pharmaceutical company, announces having secured $1.4 million on new orders from international clients, as well as having completed the initial phase of production scale-up at its Steri-Med Pharma ("Steri-Med") plan. The initial phase of production scale up has contributed to more than double the plant capacity compared to 2023 levels, and enabled Steri-Med to win new international contracts for its existing products.
Read more at newswire.ca
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
